Efficacy of trabectedin in malignant solitary fibrous tumors: A retrospective analysis from the French Sarcoma Group

J. Khalifa; M. Ouali; L. Chaltiel; S. Le Guellec; A. Le Cesne; J. Y. Blay; P. Cousin; L. Chaigneau; E. Bompas; S. Piperno-Neumann; B. Bui-Nguyen; M. Rios; J. P. Delord; N. Penel; C. Chevreau

doi:10.1186/s12885-015-1697-8

Efficacy of trabectedin in malignant solitary fibrous tumors: A retrospective analysis from the French Sarcoma Group

J. Khalifa, M. Ouali, L. Chaltiel, S. Le Guellec, A. Le Cesne, J. Y. Blay, P. Cousin, L. Chaigneau, E. Bompas, S. Piperno-Neumann, B. Bui-Nguyen, M. Rios, J. P. Delord, N. Penel, C. Chevreau

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

40 Citations (Scopus)

Résumé

Background: Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe the activity of trabectedin in a retrospective, multi-center French series of patients with SFTs. Methods: Patients were mainly identified through the French RetrospectYon database and were treated between January 2008 and May 2013. Trabectedin was administered at an initial dose of 1.5 mg/m², q3 weeks. The best tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan-Meier method was used to estimate median progression-free survival (PFS) and overall survival (OS). The growth-modulation index (GMI) was defined as the ratio between the time to progression with trabectedin (TTP_n) and the TTP with the immediately prior line of treatment (TTP_n-1). Results: Eleven patients treated with trabectedin for advanced SFT were identified. Trabectedin had been used as second-line treatment in 8 patients (72.7%) and as at least third-line therapy in a further 3 (27.3%). The best RECIST response was a partial response (PR) in one patient (9.1%) and stable disease (SD) in eight patients (72.7%). Disease-control rate (DCR=PR+SD) was 81.8%. After a median follow-up of 29.2months, the median PFS was 11.6months (95 % CI=2.0; 15.2months) and the median OS was 22.3months (95 % CI=9.1months; not reached). The median GMI was 1.49 (range: 0.11-4.12). Conclusion: Trabectedin is a very promising treatment for advanced SFTs. Further investigations are needed.

langue originale	Anglais
Numéro d'article	700
journal	BMC Cancer
Volume	15
Numéro de publication	1
Les DOIs	https://doi.org/10.1186/s12885-015-1697-8
état	Publié - 15 oct. 2015

Accès au document

10.1186/s12885-015-1697-8

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Khalifa, J., Ouali, M., Chaltiel, L., Le Guellec, S., Le Cesne, A., Blay, J. Y., Cousin, P., Chaigneau, L., Bompas, E., Piperno-Neumann, S., Bui-Nguyen, B., Rios, M., Delord, J. P., Penel, N., & Chevreau, C. (2015). Efficacy of trabectedin in malignant solitary fibrous tumors: A retrospective analysis from the French Sarcoma Group. BMC Cancer, 15(1), Article 700. https://doi.org/10.1186/s12885-015-1697-8

@article{4208be3dafe34c92a827fbff68a98cf5,

title = "Efficacy of trabectedin in malignant solitary fibrous tumors: A retrospective analysis from the French Sarcoma Group",

abstract = "Background: Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe the activity of trabectedin in a retrospective, multi-center French series of patients with SFTs. Methods: Patients were mainly identified through the French RetrospectYon database and were treated between January 2008 and May 2013. Trabectedin was administered at an initial dose of 1.5 mg/m2, q3 weeks. The best tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan-Meier method was used to estimate median progression-free survival (PFS) and overall survival (OS). The growth-modulation index (GMI) was defined as the ratio between the time to progression with trabectedin (TTPn) and the TTP with the immediately prior line of treatment (TTPn-1). Results: Eleven patients treated with trabectedin for advanced SFT were identified. Trabectedin had been used as second-line treatment in 8 patients (72.7%) and as at least third-line therapy in a further 3 (27.3%). The best RECIST response was a partial response (PR) in one patient (9.1%) and stable disease (SD) in eight patients (72.7%). Disease-control rate (DCR=PR+SD) was 81.8%. After a median follow-up of 29.2months, the median PFS was 11.6months (95 % CI=2.0; 15.2months) and the median OS was 22.3months (95 % CI=9.1months; not reached). The median GMI was 1.49 (range: 0.11-4.12). Conclusion: Trabectedin is a very promising treatment for advanced SFTs. Further investigations are needed.",

keywords = "Growth modulation index, Malignant solitary fibrous tumor, Sarcoma, Trabectedin",

author = "J. Khalifa and M. Ouali and L. Chaltiel and {Le Guellec}, S. and {Le Cesne}, A. and Blay, {J. Y.} and P. Cousin and L. Chaigneau and E. Bompas and S. Piperno-Neumann and B. Bui-Nguyen and M. Rios and Delord, {J. P.} and N. Penel and C. Chevreau",

note = "Publisher Copyright: {\textcopyright} 2015 Khalifa et al.",

year = "2015",

month = oct,

day = "15",

doi = "10.1186/s12885-015-1697-8",

language = "English",

volume = "15",

journal = "BMC Cancer",

issn = "1471-2407",

number = "1",

}

Khalifa, J, Ouali, M, Chaltiel, L, Le Guellec, S, Le Cesne, A, Blay, JY, Cousin, P, Chaigneau, L, Bompas, E, Piperno-Neumann, S, Bui-Nguyen, B, Rios, M, Delord, JP, Penel, N & Chevreau, C 2015, 'Efficacy of trabectedin in malignant solitary fibrous tumors: A retrospective analysis from the French Sarcoma Group', BMC Cancer, VOL. 15, Numéro 1, 700. https://doi.org/10.1186/s12885-015-1697-8

TY - JOUR

T1 - Efficacy of trabectedin in malignant solitary fibrous tumors

T2 - A retrospective analysis from the French Sarcoma Group

AU - Khalifa, J.

AU - Ouali, M.

AU - Chaltiel, L.

AU - Le Guellec, S.

AU - Le Cesne, A.

AU - Blay, J. Y.

AU - Cousin, P.

AU - Chaigneau, L.

AU - Bompas, E.

AU - Piperno-Neumann, S.

AU - Bui-Nguyen, B.

AU - Rios, M.

AU - Delord, J. P.

AU - Penel, N.

AU - Chevreau, C.

PY - 2015/10/15

Y1 - 2015/10/15

N2 - Background: Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe the activity of trabectedin in a retrospective, multi-center French series of patients with SFTs. Methods: Patients were mainly identified through the French RetrospectYon database and were treated between January 2008 and May 2013. Trabectedin was administered at an initial dose of 1.5 mg/m2, q3 weeks. The best tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan-Meier method was used to estimate median progression-free survival (PFS) and overall survival (OS). The growth-modulation index (GMI) was defined as the ratio between the time to progression with trabectedin (TTPn) and the TTP with the immediately prior line of treatment (TTPn-1). Results: Eleven patients treated with trabectedin for advanced SFT were identified. Trabectedin had been used as second-line treatment in 8 patients (72.7%) and as at least third-line therapy in a further 3 (27.3%). The best RECIST response was a partial response (PR) in one patient (9.1%) and stable disease (SD) in eight patients (72.7%). Disease-control rate (DCR=PR+SD) was 81.8%. After a median follow-up of 29.2months, the median PFS was 11.6months (95 % CI=2.0; 15.2months) and the median OS was 22.3months (95 % CI=9.1months; not reached). The median GMI was 1.49 (range: 0.11-4.12). Conclusion: Trabectedin is a very promising treatment for advanced SFTs. Further investigations are needed.

AB - Background: Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe the activity of trabectedin in a retrospective, multi-center French series of patients with SFTs. Methods: Patients were mainly identified through the French RetrospectYon database and were treated between January 2008 and May 2013. Trabectedin was administered at an initial dose of 1.5 mg/m2, q3 weeks. The best tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan-Meier method was used to estimate median progression-free survival (PFS) and overall survival (OS). The growth-modulation index (GMI) was defined as the ratio between the time to progression with trabectedin (TTPn) and the TTP with the immediately prior line of treatment (TTPn-1). Results: Eleven patients treated with trabectedin for advanced SFT were identified. Trabectedin had been used as second-line treatment in 8 patients (72.7%) and as at least third-line therapy in a further 3 (27.3%). The best RECIST response was a partial response (PR) in one patient (9.1%) and stable disease (SD) in eight patients (72.7%). Disease-control rate (DCR=PR+SD) was 81.8%. After a median follow-up of 29.2months, the median PFS was 11.6months (95 % CI=2.0; 15.2months) and the median OS was 22.3months (95 % CI=9.1months; not reached). The median GMI was 1.49 (range: 0.11-4.12). Conclusion: Trabectedin is a very promising treatment for advanced SFTs. Further investigations are needed.

KW - Growth modulation index

KW - Malignant solitary fibrous tumor

KW - Sarcoma

KW - Trabectedin

UR - http://www.scopus.com/inward/record.url?scp=84944402876&partnerID=8YFLogxK

U2 - 10.1186/s12885-015-1697-8

DO - 10.1186/s12885-015-1697-8

M3 - Article

C2 - 26472661

AN - SCOPUS:84944402876

SN - 1471-2407

VL - 15

JO - BMC Cancer

JF - BMC Cancer

IS - 1

M1 - 700

ER -